Satheesh P et al
However, a large Taiwanese cohort study of 11.7 million obese individuals found that GLP-1 RAs, particularly semaglutide, were associated with increased risk of depression, anxiety, and suicidal behavior [10]
RAASis with the maximally recommended or maximally tolerated dose of ACEi or ARB are the standard of care for prevention and treatment of CKD in people with diabetes, and they provide benefit over and above the effect of controlling BP [13]
A licensed provider reviews your history, including where you are in the menopause transition, before deciding what is appropriate for you
Despite ongoing efforts, most neuroprotectants have failed to demonstrate significant benefits in clinical trials, underscoring the need for novel mechanistic approaches
The insulin sensitivity improvements deserve specific mention